Mind Medicine Inc (NEO: MMED) has entered into an exclusive collaboration with Professor Dr. Liechti’s laboratory at the University Hospital Basel located in Switzerland.
The Liechti Lab, located at the University of Basel in Switzerland is lead Professor Dr. Mathias Liechti, who is one of the world’s main experts on LSD research. He is a professor of clinical pharmacology and internal medicine at the university, and currently has several planned and ongoing clinical trials pertaining to LSD as a treatment for various anxiety disorders. These clinical trials are in line with MindMed’s consideration of initiating a drug development program for such treatments.
Under the collaboration with the Liechti Lab, MindMed will provide support for those ongoing and planned clinical trials regarding LSD and anxiety disorders via milestone payments and research funding. In return for supporting Dr, Liechti’s research, MindMed will be granted the exclusive licensing to the data and IP developed from the studies. In the event that the collaboration produces products for marketing, the university will receive development revenue and royalties in return.
Sponsored · Cambria Gold Mines
As per the details of the agreement, MindMed will be granted exclusive patent rights and rights to compounds and data which not only pertain to LSD research but other psychedelic compounds as well. Presently, MindMed is already working alongside Dr. Liechti, filing various patents for the current clinical trials and data which were generated 10 years ago and onward.
Mind Medicine Inc is a neuro-pharmaceutical company with a focus on discovering and developing psychedelic medicines. The company is currently trading at $0.66 on the NEO Exchange.
Information for this briefing was found via Sedar and Mind Medicine Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
